Trial Outcomes & Findings for PED NEONAT 20-000599 Fetal Body Composition (NCT NCT04508751)

NCT ID: NCT04508751

Last Updated: 2023-08-30

Results Overview

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Visceral adipose tissue PDFF values will be directly measured from regions of interest.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

23 participants

Primary outcome timeframe

During the procedure (MRI)

Results posted on

2023-08-30

Participant Flow

Recruited by study investigator or obstetrician through medical clinic.

One subject was excluded due to inability to schedule MRI scan

Participant milestones

Participant milestones
Measure
Healthy Pregnancy
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines. Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded. 3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
Pregnant Mothers With Gestational Diabetes
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines. Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded. 3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
Pregnant Mothers With Infants Diagnosed With IUGR
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines. Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded. 3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
Overall Study
STARTED
10
5
7
Overall Study
COMPLETED
10
5
5
Overall Study
NOT COMPLETED
0
0
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Healthy Pregnancy
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines. Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded. 3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
Pregnant Mothers With Gestational Diabetes
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines. Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded. 3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
Pregnant Mothers With Infants Diagnosed With IUGR
Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines. Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded. 3T "Free-Breathing" Fetal Magnetic Resonance Imaging: Subject will have a one time MRI scan.
Overall Study
Discontinued study early due to maternal discomfort
0
0
2

Baseline Characteristics

PED NEONAT 20-000599 Fetal Body Composition

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
Total
n=20 Participants
Total of all reporting groups
Age, Continuous
34.5 years
n=5 Participants
33 years
n=7 Participants
35 years
n=5 Participants
34.5 years
n=4 Participants
Sex: Female, Male
Female
10 Participants
n=5 Participants
5 Participants
n=7 Participants
5 Participants
n=5 Participants
20 Participants
n=4 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=5 Participants
4 Participants
n=7 Participants
1 Participants
n=5 Participants
7 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
8 Participants
n=5 Participants
1 Participants
n=7 Participants
4 Participants
n=5 Participants
13 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Asian
3 Participants
n=5 Participants
0 Participants
n=7 Participants
2 Participants
n=5 Participants
5 Participants
n=4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
White
7 Participants
n=5 Participants
5 Participants
n=7 Participants
3 Participants
n=5 Participants
15 Participants
n=4 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Region of Enrollment
United States
10 participants
n=5 Participants
5 participants
n=7 Participants
5 participants
n=5 Participants
20 participants
n=4 Participants
Glucose tolerance test at 1 hour
87 mg/dL
n=5 Participants
182 mg/dL
n=7 Participants
131 mg/dL
n=5 Participants
109 mg/dL
n=4 Participants

PRIMARY outcome

Timeframe: During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Visceral adipose tissue PDFF values will be directly measured from regions of interest.

Outcome measures

Outcome measures
Measure
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
Maternal Visceral Adipose Tissue Volume
97593 mm3
Interval 78014.0 to 121081.0
169626 mm3
Interval 137736.0 to 227035.0
96787 mm3
Interval 82327.0 to 184784.0

PRIMARY outcome

Timeframe: During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images. The distribution/extent of hepatic fat will be manually delineated/drawn on the 3D MRI images and PDFF maps. This work will be performed by PI Strobel with validation from PI Wu.

Outcome measures

Outcome measures
Measure
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
Fetal Liver PDFF
3.2 percentage of triglycerides/
Interval 3.0 to 3.3
5.2 percentage of triglycerides/
Interval 4.2 to 5.5
1.9 percentage of triglycerides/
Interval 1.4 to 3.7

SECONDARY outcome

Timeframe: During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Subcutaneous adipose tissue PDFF values will be directly measured from regions of interest.

Outcome measures

Outcome measures
Measure
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
Fetal Subcutaneous Tissue Volume
241 mm3
Interval 232.0 to 255.0
280 mm3
Interval 261.0 to 295.0
220 mm3
Interval 205.0 to 235.0

SECONDARY outcome

Timeframe: During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images. The distribution/extent of subcutaneous fat will be manually delineated/drawn on the 3D MRI images and PDFF maps and used to calculate volume of subcutaneous adipose tissue. This work will be performed by PI Strobel with validation from PI Wu.

Outcome measures

Outcome measures
Measure
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
Maternal Subcutaneous Tissue Volume
157319 mm3
Interval 126300.0 to 200028.0
216264 mm3
Interval 161461.0 to 325975.0
159197 mm3
Interval 84024.0 to 339707.0

SECONDARY outcome

Timeframe: During the procedure (MRI)

MRI data will be reconstructed by Siemens scanner software to produce 3D fat-water separated images and PDFF maps. The FB-MRI radial data will be transferred to a separate workstation for custom reconstruction of 3D fat-water-separated images and PDFF maps and analysis. Hepatic adipose tissue PDFF values will be directly measured from regions of interest.

Outcome measures

Outcome measures
Measure
Healthy Pregnancy
n=10 Participants
Pregnancy without fetal anatomic or chromosomal abnormalities, FGR, or GDM.
Pregnant Mothers With Gestational Diabetes
n=5 Participants
GDM was defined as a positive glucola screen at 26 to 32 weeks gestation.
Pregnant Mothers With Infants Diagnosed With IUGR
n=5 Participants
IUGR was defined as fetal weight and abdominal circumference \<10th percentile on ultrasound for a given gestational age or per obstetrician documentation on at least two medical notes
Maternal Hepatic Fat PDFF
2.1 % triglycerides
Interval 1.8 to 2.8
3.2 % triglycerides
Interval 2.1 to 3.8
2.2 % triglycerides
Interval 1.1 to 5.0

Adverse Events

Healthy Pregnancy

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Pregnant Mothers With Gestational Diabetes

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Pregnant Mothers With Infants Diagnosed With IUGR

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Kara Calkins

University of California Los Angeles

Phone: 3108259330

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place